(c) what is the provision of DPCO, 1979 under which loan from DPEA can be given;

(d) whether the sanction for payment of loan was given at his level;

(e) what are the terms under which such a loan is given;

(f) what is the interest being charged and in how many instalments the loan is repayable;

(g). what is the total amount recovered under DPEA from 1980 to 31st October, 1988; and

(h) what are the details of amount given under other purposes alongwith the name of each Drug company?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) No, Sir.

(b) to (f) Do not arise.

(g) The total amount so far recovered under DPEA is about Rs. 1813.74 lakhs.

(h) The details of amount paid to drug companies under the provisions of DPCO from DPEA is given in the Statement, to the extent the information is available.

Statement

Name of the Companies ^	Total Amount Paid (Rs.)
M/s. Indian Drugs & Pharmaceuticals Ltd.	10,32,82,026.89
M/s. Hindustan Antibiotics Ltd.	3,43,78,457.77
M/s. Jayant Vitamins Ltd. .	20,24,832.00
M/s. Boehringer Knoll Ltd.	27,17,729.70
M/s. Parke Davis Ltd.	16,73,645.90
M/s. Sunil Synchem Ltd.	25,50,130.00
M/s. Bengal Chemicals & Pharmaceuticals Ltd.	9,13,204.50
M/s. Alembic Chemicals Ltd.	38,24,000.00
M/s. Andhra Sugars Ltd.	11,95,647.00
M/s. Max India Ltd.	2,16.18,000.00
M/s. Pharmachem Ltd. .	12,58,000.00
M/s. Gujarat Lyka Ltd. .	38,51,000.00
	17,92,86,673.76

Revision of Leader Price

1411. SHRl CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 397 given in the Rajya Sabha on the 29th August, 1988 and state;

(a) whether it is a fact that his Ministry has revised the Leader price of formulations based on Trimethoprim and Sulphamethoxazole;

(b) what was the earlier price and what is the revised price;

(c) whether it is a fact that there was no increase in the notified prices of these bulk drugs and both these bulk drugs are being sold in the open market at much less price than the notified price;

(d) if so, what are the basis for increasing the leader price of formulations;

(e) whether it is also a fact that specific communication was sent to BICP for seeking their recommendations for revision of leader prices; and

(f) if so, what are the details thereof and who sent the communication to BICP?

THE MINISTER OF INDUSTRY (SHRIJ. VENGAL RAO): (a) Yes, Sir.

(b) ThJe required details to the extent available are given in the statement at annexure. [See Appendix CXLVTJl Annexure No. 61].

(c) Prices of bulk drugs Trimethoprim and Sulphamethoxazole have not been revised under DPCO, 1987. The market prices of these bulk drugs keep fluctuating.

(d) The ceiling prices for formulations based on these bulk drugs were revised by allowing incidental charges at 8 per cent on the notified prices of bulk drugs.

(e) No Sir.

(f) Does not arise.

Basis for working out the overcharging Amounts

1412. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 2631 given in the Rajya Sabha on the 29th August, 1988 and state;

(a) whether it is a fact that the undue benefit assessed by the com* mittee is based on the production ot Baralgon Ketone, Pheniramine, Glibenclamide and Fursemide;

(b) whether it is also a fact that the consumer has been overcharged on finished formulations based on these drugs;

(c) what are the basis of working the rate of recovery of each pack and strength of finished formulations based on these drugs in the absence <*A* approved prices of all the packs and strengths of formulations;

(d) whether it is a fact that production of bulk drugs and production of formulations based on each bulk drugs shows large gap; and

(e) if so, the extent of gap yearwise and the reasons therefor?

THE MINISTER OF INDUSTRY. (SHRI J. VENGAL RAO): (a) to (e) The required details to the extent available would be collected and laid on the Table of the House.

Non-Implementation of Government Fixed Prices by M/s. Pfizer

1413. SHRi CHANDRIKA PRASAD TRIPATHI: Will the Minister of IN DUSTRY be pleased to refer to the answer to Unstarred Question 3286 given in the Rajya Sabha on the 22nd August, 1988 and state:

(a) what were the prices of various salts of Oxytetracycline and Sodium PAS before the commencement of DPCO, 1979 and what were the prices of these drugs as fixed under DPCO, 1979 for the first time;

(b) what were the purchases of Oxytetracycline by M/s. Pfizer from 1979-80 to date from outside sources and at what price were these purchases made;

(c) what are the names of 21 Products for which Pfizer had not implemented the Government fixed prices and they were served with show cause notice; and

(d) when was this notice issued and" what steps were taken after the notice?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (d) The required details, to the extent available, would be collected and laid on the Table of the House.

Amount due from M/s. Cyanamide

1414. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of IN DUSTRY be pleased to refer to the answer to Unstarred Question 3281 given in the Rajya Sabha On the 22nd August, 1988 and state:

(a) whether it is a fact that amount due from Cyanamid under DPEA